Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
The primary objective of the study is to assess the clinical efficacy of Rebif® 44 microgram (mcg) three times per week compared with Copaxone® 20 milligram (mg) daily in subjects with relapsing Multiple Sclerosis.
Epistemonikos ID: 0b2053a8450746445dc1e5d9ae93806524344751
First added on: Mar 30, 2022